• Ensuring the proactive, and proportionate, collection of high-quality medicines safety data through risk management systems. This would also involve single case and periodic reporting of suspected ADRs

• Involving stakeholders in pharmacovigilance, including through direct patient reporting of suspected ADRs and the inclusion of patients and heath-care professionals in decision-making

• Simplifying the current community pharmacovigilance procedures with consequent efficiency gains for both the pharmaceutical industry and medicines regulators.